新世界发展(00017.HK)香港及内地合同销售均超过销售目标
格隆汇8月12日丨新世界发展(00017.HK)发布公告,截至2019年6月30日止财政年度,集团于中国香港的应占物业合同销售金额约为105亿港元,超过100亿港元的销售目标。住宅销售主要包括傲泷,柏蔚山,瑧尚,瑧桦及瑧颐。其中于2019年上半年推出的瑧尚及瑧桦经已售罄。
中国内地整体物业合同销售金额约为人民币198亿元,超过人民币160亿元的销售目标,其中,位于大湾区内广州及深圳的重点项目占销售贡献超过一半。
公告表示,良好的执行力及销售策略是公司的强劲优势,在未来一段时间,拥有超过3000个单位的港铁大围站住宅项目,以及可销售面积约11万平方米的深圳太子湾项目,将会陆续分批推出。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.